<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161126031095N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-21</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of adding Dexamethasone and Fentanyl to Bupivacaine in transverse abdominal plane block (TAP) on pain intensity after cesarean section by spinal anesthesia  in Sari Emam hospital in 1401</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of adding Dexamethasone and Fentanyl to Bupivacaine in transverse abdominal plane block (TAP) on pain intensity after cesarean section by spinal anesthesia  in Sari Emam hospital in 1401</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70549</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: There are different methods for random allocation in clinical trial studies, which is one of these methods, and in cases such as when the number in each group is to be selected in equal proportion, this method is appropriate. The size of each block is usually determined as a multiple of 4 or six or eight and so on. The size of all blocks can be considered as a fixed number or it can be considered variable based on the mentioned multiples. After selecting the eligible samples, in this study, randomization will be done by Block Randomization method. became. This process will be done with random allocation software. With the mentioned software, 10 blocks of six will be created. Samples will be assigned to each group based on randomly generated numbers, Blinding description: Before starting the study, the list of people will be randomly assigned to 2 study groups using a computer. Based on this list, envelopes are prepared, inside which the name of one of the treatment groups is written based on the list of random numbers. These envelopes will be provided to the first expert, and if the patients meet the entry criteria, an envelope will be opened for each patient and their treatment group will be determined based on it. The drug is prepared for injection by the mentioned expert and is handed over to the second expert (who does not know the type of drug) and finally the drug is given to the anesthesia assistant performing TAP Block. The completer of the checklist also has no knowledge of the drug group assigned to each patient.</study_design>
      <phase>2</phase>
      <hc_freetext>Other acute postprocedural pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 50 micrograms of fentanyl plus 17 ml of 0.25% bupivacaine and 2 ml of 0.9% normal saline in a total volume of 20 ml on each side. Intervention 2: Intervention group: 4 mg of dexamethasone plus 17 ml of 0.25% bupivacaine and 2 ml of 0.9% normal saline in a total volume of 20 ml on each side.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is "There is no further information".</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alieh Zamani Kiasari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Clinical Research Development Center, Imam Khomeini Hospital, Amir Mazandarani Boulevard</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48166-33131</zip>
        <telephone>+98 11 3335 5080</telephone>
        <email>aliehzamani@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alieh Zamani Kiasari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Clinical Research Development Center, Imam Khomeini Hospital, Amir Mazandarani Boulevard</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48166-33131</zip>
        <telephone>+98 11 3335 5080</telephone>
        <email>aliehzamani@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18-50 years old
Patients undergoing cesarean section under spinal anesthesia
Patients with American Society of Anesthesiology (ASA) class I and II anesthesia status (ASA definition = healthy patient without organic, biochemical or mental disease and ASAII = patient with mild systemic disease such as mild asthma - controlled hypertension - disease has no effect on activity not daily - the possibility of affecting anesthesia and surgery)
Patients who can perceive and evaluate their pain on a visual analog pain scale. (VAS; scale 0-10)
They were eligible to provide written informed consent to enroll in the study
Body mass index kg/m2 = 23.9-18.5
Absence of coagulopathy
No alcohol or drug addiction</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having chronic pain, or having underlying diseases such as moderate or severe heart, kidney, lung or nerve diseases, significant scoliosis or kyphosis, excessive obesity
Taking painkillers before surgery
Infection at the injection site
History of abdominal surgery or trauma
Respiratory tract infection within 2 weeks
New York Heart Association Class &gt;II cardiac status and psychiatric disorders that interfere with pain perception and evaluation
They had a history of anaphylaxis using bupivacaine
Patients who did not tolerate spinal anesthesia well and had to be converted to general anesthesia for cesarean section
Individuals who could not provide informed consent or patients who did not wish to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 50 micrograms of fentanyl plus 17 ml of 0.25% bupivacaine and 2 ml of 0.9% normal saline in a total volume of 20 ml on each side</i_keyword>
      <i_keyword>Intervention group: 4 mg of dexamethasone plus 17 ml of 0.25% bupivacaine and 2 ml of 0.9% normal saline in a total volume of 20 ml on each side</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postpartum pain intensity. Timepoint: 0/2/4/6/12 and 24/hours after the operation. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Sedation. Timepoint: 0/2/4/6/12 and 24/hours after the operation. Method of measurement: Sedation criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-13</approval_date>
        <contact_name>Ethics Committee of Imam Khomeini Hospital of Sari - Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Office Building Ethics Committee of Imam Khomeini Hospital Amir Mazandarani Blvd. Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
